Italy’s Recordati has posted a reasonable set of financials for the first quarter, which show that net income climbed 9.3% to 27.6 million euros.

Sales were up 6.9% to 183.7 million euros, boosted by international revenues, which increased 11.7% to 128.2 million euros. Recent acquisitions, such as the purchase of Turkey’s Yeni Ilac and Czech drugmaker Herbacos-Bofarma, contributed to growth, helping to offset a 1.4% sales decline in Italy.

Recordati noted that it launched the combination hypertensive Zanextra (lercanidipine/enalapril) in France, “the largest market for lercanidipine worldwide”. The drug, which the firm will be hoping reduces reliance on its main growth driver Zanidip/Lercadip (lercanidipine) is already available in Germany, Australia, Ireland, Finland, Denmark, Greece, South Africa and the Netherlands.

The Milan-based group added that its performance this year has been in line with expectations and “for the next quarters of 2009 a positive trend is foreseen that will allow us to reach the targets already announced". This is a reference to an earlier guidance of 750 million euros in sales,

The group is targeting 2009 sales of 750 million euros, up %, operating profit of 155 million euros (+7%) and net income of 105 million euros, (+5%).